




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Original Research

A scheme for inferring viral-host associations based on codon usage patterns identifies the most affected signaling pathways during COVID-19

Jayanta Kumar Das^a, Subhadip Chakraborty^b, Swarup Roy^{c,*}

^a Department of Pediatrics, Johns Hopkins University, School of Medicine, MD, USA

^b Department of Botany, Nabadwip Vidyasagar College, Nabadwip, India

^c Network Reconstruction & Analysis (NetRA) Lab, Department of Computer Applications, Sikkim University, Gangtok, India



ARTICLE INFO

Keywords:

Protein interaction network
Codon usage bias
Bipartite graph
Cell signaling
Relative synonymous codon usage
Centrality
Drugs

ABSTRACT

Understanding the molecular mechanism of COVID-19 pathogenesis helps in the rapid therapeutic target identification. Usually, viral protein targets host proteins in an organized fashion. The expression of any viral gene depends mostly on the host translational machinery. Recent studies report the great significance of codon usage biases in establishing host-viral protein-protein interactions (PPI). Exploring the codon usage patterns between a pair of co-evolved host and viral proteins may present novel insight into the host-viral protein interactomes during disease pathogenesis. Leveraging the similarity in codon usage patterns, we propose a computational scheme to recreate the host-viral protein-protein interaction network. We use host proteins from seventeen (17) essential signaling pathways for our current work towards understanding the possible targeting mechanism of SARS-CoV-2 proteins. We infer both negatively and positively interacting edges in the network. Further, extensive analysis is performed to understand the host PPI network topologically and the attacking behavior of the viral proteins. Our study reveals that viral proteins mostly utilize codons, rare in the targeted host proteins (negatively correlated interaction). Among them, non-structural proteins, NSP3 and structural protein, Spike (S), are the most influential proteins in interacting with multiple host proteins. While ranking the most affected pathways, MAPK pathways observe to be the worst affected during the SARS-CoV-2 infection. Several proteins participating in multiple pathways are highly central in host PPI and mostly targeted by multiple viral proteins. We observe many potential targets (host proteins) from the affected pathways associated with the various drug molecules, including *Arsenic trioxide*, *Dexamethasone*, *Hydroxychloroquine*, *Ritonavir*, and *Interferon beta*, which are either under clinical trial or in use during COVID-19.

1. Introduction

The entire world is passing through an unprecedented pandemic situation due to massive outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infected viral disease, COVID-19. SARS-CoV-2 belongs to the *Coronaviridae* family, and members of this family are enveloped, non-segmented, and have single-stranded, positive-sense large RNA genomes [1]. This virus rapidly spreads from person to person through respiratory droplets during close physical contact. Other than respiratory system, it is reported to attack the immune system, and other vital cellular machinery leading to multi-organ failure [2]. The need for the hour is utmost crucial for the scientific community to understand the disease pathogenesis of SARS-CoV-2 at genomic and proteomic levels for the rapid development of effective drugs or vaccines to control the

COVID-19. Many recent works use host-viral protein-protein interaction network as an input to elucidate potential drug targets or repurposed drug molecules [3–5]. Host-pathogen protein interactions provide essential insights into the molecular mechanisms of pathogenesis [6].

The host defense mechanism activates signal transduction molecules that initiate signals, which activate immune effector mechanisms to protect the host from any pathogenic infections. Studies show that viral immune modulators perturb the human PPI network by targeting signaling pathways [7] to suppress the immunity in mammalian hosts [8]. To understand the molecular mechanism of pathogenicity of SARS-CoV-2 during COVID-19 disease, investigation of the host-viral protein interactions is important. Knowledge gained through understanding the interactions among viral and host proteins involved in signaling pathways may translate into effective therapies and vaccines. There are four

* Corresponding author.

E-mail address: sroy01@cus.ac.in (S. Roy).

<https://doi.org/10.1016/j.jbi.2021.103801>

Received 24 September 2020; Received in revised form 2 May 2021; Accepted 3 May 2021

Available online 7 May 2021

1532-0464/© 2021 Elsevier Inc. This article is made available under the Elsevier license (<http://www.elsevier.com/open-access/userlicense/1.0/>).

(04) basic categories of chemical signaling found in multi-cellular organisms namely; paracrine signaling, autocrine signaling, endocrine signaling, and signaling by direct contact. Various regulatory signaling pathways are involved in signaling transduction and cellular interactions, many of which are playing an important role during COVID-19. Signal transduction focuses on molecular and functional aspects of viral interactions with host cell signaling, important for the anti-viral response, the viral life cycle, viral pathogenesis, and cell transformation [9]. We aim to study the interaction pattern of SARS-CoV-2 with its target host proteins involved in signaling pathways [10–15] (see Materials and Method section). Working with them can help in deciphering the possible involvement of pathways and key genes during COVID-19 pathogenesis.

The virus-host interactome is essential for understanding virulence factors influencing SARS-CoV-2 pathogenesis [16]. Recent studies reported the use of SARS-CoV-2 and host PPI networks to study the pathogenesis of SARS-CoV-2 and identify repurposed drugs [17,4,18]. Several studies have shown that viral proteins interact with hubs in complex host PPI networks [19,20]. Considering different features of proteins such as sequence homology, gene co-expression, or phylogenetic profiles [21–23], the pairwise similarity is computed between a pair of proteins to predict a possible interaction between them. In addition to non-structural information, structural data about a pair of proteins appears to be more effective in improving prediction [24,25,4].

Several computational methods have been developed to predict PPIs by focusing on protein sequence features [26–28]. In reality, predicting whether two given proteins are physically interacting or not based on the similarity of different structural and non-structural features is challenging and not feasible due to the expensive experimental setup. In the case of viral genome study, codon usage biases play an important role [29–31]. Viral gene depends largely on the host translational machinery for their expression [32]. Viral proteins are co-evolved with host proteins. Several studies have reported that physically interacting or functionally associated protein pairs have similar codon usage bias [33–39]. Therefore, codon usage bias can be utilized in establishing host-viral protein interactions [40,41]. State-of-the-art methods for inferring interactions do not consider the co-expression or co-adaptation between a pair of virus and host proteins for drawing possible attacking mechanisms of a virus [42,43]. According to the genome hypothesis proposed by Grantham et al. [44], the pattern of codon usage is species-specific and in some way unique. Interestingly, even in the same genome, the codon usage varies significantly among genes with different expression levels [39], functions [45], and tissue-specific patterns [46]. Few works hypothesized that viral proteins enrich with few codons that are rare in their target host proteins [47,48].

In this work, we explore host-viral interactions by leveraging the inherent correlation (co-expression or co-adaptation) between viral and host proteins' codon usage patterns, which applies to any nucleotide (CDS) sequences. To the best of our knowledge, no prior work explored the codon usage similarity to infer host-viral PPI network. We capture both positive and negative interactions in the host-viral PPI. We use host proteins involved in different human cellular signaling pathways that might be affected during COVID-19 disease pathogenesis. Topologically, we try to establish the relevance of the host proteins and highlight a few essential proteins in the network, which are also useful as potential drug targets for certain reported drugs during COVID-19.

2. Materials and method

This section discusses the proposed scheme for constructing a host-viral PPI network using pair-wise codon usage patterns of host and viral proteins. To analyze the interaction mechanism of SARS-CoV-2 viral proteins in host signaling pathways, we select all the genes involved in 17 candidate signaling pathways. We calculate the RSCU similarity score for all pairs of host-viral candidate proteins to build the network. We further analyze the host PPI network to list highly

Table 1
SARS-CoV-2 proteins considered for host-viral PPI construction.

Protein category	Count	Protein Name
Structural	4	Spike (S), Envelope (E), Membrane (M), Nucleocapsid (N)
Non-structural	16	Nsp1, Nsp2, ..., Nsp16
Accessory	6	Orf3a, Orf6, Orf7a, Orf7b, Orf8, Orf10

connected host proteins and highlighted a few potential drugs targeting those proteins for possible repairing of affected pathways during COVID-19.

2.1. Data acquisition and processing

Structurally, SARS-CoV-2 consists of three categories of proteins, structural, non-structural, and accessory proteins. We select four (04) structural proteins, sixteen (16) non-structural proteins, and six (06) accessory proteins reported in [49,50]. The details of the viral proteins are listed in Table 1 (NCBI accession numbers for SARS-CoV-2 proteins: MN908947.3, NC_045512).

As discussed before, we consider seventeen (17) signaling pathways, namely *TGF- β* , *JAK-STAT*, *PI3K-Akt*, *MAPK*, *HIF-1*, *TNF*, *NF- κ B*, *Cytokine-cytokine receptor interaction*, *Apoptosis*, *Th17 cell differentiation*, *Chemokine*, *Toll-like receptor*, *RIG-like receptor*, *IL-17*, *Insulin Signaling*, *mTOR*, and *Adipocytokine*, which are reported to associate with COVID-19 and other viral diseases [10–15,51–53]. We search the Kyoto Encyclopedia of Genes and Genomes (KEGG) database¹ for the set of human host proteins (genes) that participated in our selected candidate pathways. We observe a total of 2600 genes involved in the above pathways (Supplementary-A, Table S1). We use 1313 unique genes participating exclusively in our 17 target pathways (Supplementary-B). Our proposed scheme is relying on the codon usage pattern, for which the nucleotide sequence (coding region) of each host protein is obtained from the NCBI database. A good number of genes (total 1274) are also involved in more than one pathways. We summarize our target pathways and the number of genes involved in each pathway in the Table 2.

2.2. Computing Relative Synonymous Codon Usage (RSCU)

The genetic code describes how the 64-nucleotide triplets specify only twenty (20) different translated amino acids. These alternative codons for the same amino acids are termed as *synonymous codons*. However, most of the amino acids have at least two synonymous codons that are not used at the same frequencies in different genomes. Differences in the frequency of occurrence on synonymous codons in coding DNA is termed as synonymous codon usage bias [54].

Several indices are available to quantify the synonymous codon usage bias [55]. Effective Number of Codons (ENC) focuses on GC content, Rare Codon (RC) focuses on the abundance of low usage codon, and Codon Adaptation Index (CAI) calculates the frequency of the overall codons based on a reference set. They are either partially capturing the usage or generating values based on the relative whole reference set. We are looking for a normalized frequency of codon usage for comparing the variation of usage between host and viral proteins. RSCU is one of the indices for measuring codon bias used to examine synonymous codon usage without the confounding influence of the amino acid composition of different gene products [55]. It is widely used to estimate the codon usage bias [56–59]. It can be used to quantify the similarity between any two gene sequences by applying any classical proximity measure between a pair of RSCU vectors. The similarity between RSCU vectors may reflect the possible interactions between a

¹ www.genome.jp/kegg/pathway.html.

Table 2

Candidate signaling pathways and the number of host proteins (or genes) participating in the pathway.

Pathways	#Genes involved	Pathways	#Genes involved
NF-κ B signaling pathway	105	Th17 cell differentiation1	108
Cytokine-cytokine receptor interaction	295	TGF-β signaling pathway	95
TNF signaling pathway	113	Toll-like receptor signaling pathway	105
IL-17 signaling pathway	95	HIF-1 signaling pathway	110
RIG-I-like receptor signaling pathway	70	Apoptosis	137
MAPK signaling pathway	295	Insulin signaling pathway	138
Chemokine signaling pathway	190	mTOR signaling pathway	156
PI3K-Akt signaling pathway	355	Adipocytokine signaling pathway	70
JAK-STAT signaling pathway	163		

couple of proteins in the PPI [58,60,57].

RSCU is the ratio between the observed number of occurrences of codons and expected during uniform usage of synonymous codons and calculated as follows.

$$RSCU_{ij} = \frac{X_{ij}}{\frac{1}{n_i} \sum_{j=1}^{n_i} X_{ij}}, \tag{1}$$

where, X_{ij} is the number of occurrences of the j^{th} codon for the i^{th} amino acid, which is encoded by n_i synonymous codons. The RSCU score of a codon more than 1.0 indicates excess usage (biased) of the codon, and less than 1.0 marks low usage of that particular codon.

We generate a 59-dimensional RSCU feature vector for each coding protein. We consider the usage pattern of only 59 codons (out of 64 available codons). We ignore 03 stop codons and uniquely coded codons ATG and TGG coded for Met and Trp amino acids, respectively [61]. For RSCU calculation, we use the CAI package [62] available free at ². Using the feature vectors, we try to draw the similarity between host and viral proteins to form a network, as discussed next.

2.3. Inferring host-viral protein interaction network

Protein-Protein Interactions (PPI) are usually studied computationally from a graph-theoretic perspective [63]. Interactions among different organisms, such as a host and its pathogen, are primarily driven by interactions among the host proteins and pathogen proteins. These interactions can also be represented as host-pathogen PPI. Host-pathogen PPI is usually represented as a *bipartite graph* where any given interacting pair of nodes (proteins) does not belong to the same organism. This network essentially provides the known interactions of host proteins with pathogen proteins.

Pearson’s correlation coefficient (ρ) is used to calculate relationship between two variables with different magnitudes [64,65]. Assume $\mathcal{R}_v = \{x_1, x_2, \dots, x_{m=59}\}$ and $\mathcal{R}_h = \{y_1, x_2, \dots, y_{m=59}\}$ are the RSCU vectors for a pair of viral and host proteins, respectively. Based on \mathcal{R}_v and \mathcal{R}_h , ρ can be calculated as follows.

$$\rho(\mathcal{R}_v, \mathcal{R}_h) = \frac{\sum_{i=1}^m (x_i - \overline{\mathcal{R}_v})(y_i - \overline{\mathcal{R}_h})}{\sqrt{\sum_{i=1}^m (x_i - \overline{\mathcal{R}_v})^2} \sqrt{\sum_{i=1}^m (y_i - \overline{\mathcal{R}_h})^2}} \tag{2}$$

² <https://cai.readthedocs.io/en/latest/>.

where, $x_i \in \mathcal{R}_v$ and $y_i \in \mathcal{R}_h$, $\overline{\mathcal{R}_v}$ and $\overline{\mathcal{R}_h}$ are the mean of the vectors \mathcal{R}_v and \mathcal{R}_h respectively.

To determine significantly correlated pair of RSCU vectors, we use 2-tailed p measurement [66]. Two proteins are strongly connected if the p is less than certain cutoff threshold, τ , i.e. $p(\mathcal{R}_v, \mathcal{R}_h) < \tau$. We use SciPy version 1.5.0 (*scipy.stats*) ³ for calculating ρ and p value.

We consider two (02) kinds of interactions, positive and negative, between a host and viral proteins while inferring the network. Positive interaction indicates possible similar codon usage, whereas a negative score signifies possible rare codon usage by SARS-CoV-2 proteins compared to its interacting host proteins. The Pearson correlation coefficient (ρ) is used to determine the possible sign of the inferred edges. An example is shown in Fig. 1 for negative and positive correlations computed between two pairs of host-viral proteins.

Given a set of viral proteins, $V = \{v_1, v_2, \dots, v_n\}$ and host proteins $H = \{h_1, h_2, \dots, h_n\}$ we can create a bipartite graph in the form of adjacency matrix using the above ρ and p values as follows.

$$I_{(v_i, h_j)} = \begin{cases} +1, & \text{if } p(\mathcal{R}_{v_i}, \mathcal{R}_{h_j}) < \tau \text{ and } \rho(\mathcal{R}_{v_i}, \mathcal{R}_{h_j}) > 0 \\ -1, & \text{if } p(\mathcal{R}_{v_i}, \mathcal{R}_{h_j}) < \tau \text{ and } \rho(\mathcal{R}_{v_i}, \mathcal{R}_{h_j}) < 0 \\ 0, & \text{if } p(\mathcal{R}_{v_i}, \mathcal{R}_{h_j}) > \tau \end{cases} \tag{3}$$

Next, we investigate the interaction mechanism of SARS-CoV-2 proteins with the proteins involved in certain signaling pathways given in Table 2.

3. Results and discussion

3.1. Benchmarking

To assess the effectiveness of codon usage bias measure in predicting possible viral and host protein interactions, the reported host-viral networks with physically verified interactions are considered. For example, 332 host protein interactions with 27 SARS-CoV-2 proteins [3] (network-1) are reported that utilized affinity purification mass spectrometry (AP-MS) based method to infer the physical interactions. It reports host-viral interactions forming star-like topology, where one host is exclusively interacting with one viral node. Few other similar studies report SARS-CoV-2 viral proteins interactions with more than 1100 [67](network-2) and 200 [16](network-3) host proteins. Altogether, there are total of 294 interactions (network-1), 1106 interactions (network-2), and 517 interactions (network-3) in the above networks, which are available in BioGRID database [68]. We apply our method to these three networks, and we observe approximately 54% interactions (average) for the above three networks (Table 3). In addition, we use three (03) other viral-host networks, such as Epstein-Barr from Virhostome ⁴, Hepatitis-C and Influenza-A from VirusMINT [69] for validation. We report the performance in Table 3. For more detailed results, one can refer to *Supplementary-c*.

Unlike reported physical interactions methods, codon usage infers a possible co-expression between a pair of host and viral proteins computed quantitatively using pairwise RSCU score similarity. Possibly this might be a possible reason for inferring low matching interactions with the true networks. We consider $\tau = 0.05$ for inferring the above networks.

3.2. Comparison of RSCU patterns among viral and host proteins

We report codon usage distribution of 59 codons across 26 viral proteins (SARS-CoV-2) and 1313 host proteins in Fig. 2 (a) and (b), respectively, involved in our candidate signaling pathways. We observe that GGT, AGA, GCT, CCT, GTT, TCT, ACA, CTT, TTA, ACT are the

³ <https://scipy.org>.

⁴ http://interactome.dfci.harvard.edu/V_hostome/idex.php.




Fig. 1. The host-viral codon usage (RSCU) patterns. The scatter plot shows the RSCU value of 59 codons for viral (X-axis) and host (Y-axis) proteins. The regression line represents the trend of RSCU patterns. Viral protein S showing positive correlation ($\rho = 0.82$) with host protein TANK and negative correlation ($\rho = -0.71$) with host protein GDF15.

Table 3
Performance assessment of the proposed scheme on few virus-host interaction networks.

Virus	Source	# Viral proteins	# Host proteins	# Host-virus interactions	Matching (%)
SARS-CoV-2	Network-1 [3]	23	294	294	60
	Network-2 [67]	21	884	1106	43
	Network-3 [16]	25	203	517	59
Epstein-Barr	Virhostome ^a	19	435	1486	60
Hepatitis-C	VirusMINT [69]	2	15	15	85
Influenza-A	VirusMINT [69]	2	4	4	75

^a http://interactome.dfci.harvard.edu/V_hostome/idex.php.

highly used (median RSCU score ≥ 1.5 for each codon) codons in SARS-CoV-2 proteins. On the other hand, CGA, AGC, ACC, CCG, CTG, CCG, ACG, GCG, TCG, GGG rarely used codons. In the host proteins (from 17 signaling pathways), codons such as CTG, GTG, ATC, GCC, CAG, ACC, AGC, GGC, and CCC are highly used (median RSCU score ≥ 1.5 for each codon). The distribution margins of RSCU values of those codons are relatively wider (Fig. 2 (b)). However, CCG, GTT, CGT, GCG, TCG, CAA, CTA, ATA, GTA, TTA rarely used codons in host proteins. It is worth mentioning that for SARS-CoV-2 proteins, highly used codons are ending (third position of codon) with T or A that shows similar characteristics with *Nipah virus* [54], SARS-CoV [70], and coronavirus N genes [71]. But for host proteins from candidate signaling pathways, the highly used codons are ending with G or C at the third position of the codons.

3.3. Analysis of host-viral inferred networks

We predict the host-viral (SARS-CoV-2) interaction graph based on the Eq. 3 involving 26 SARS-CoV-2 proteins with 1313 host proteins participating in 17 signaling pathways. Out of 34138 (26×1313) maximum possible interactions, our method infers 9412 ($\approx 36\%$) strong interactions. In our network, 859 distinct host proteins ($\approx 66\%$) are connected to at least one viral protein. We set $\tau = 0.001$ for deciding the strong interaction (edge) between two proteins. Interestingly, our inferred network reveals that out of 859 host proteins, a total of 779 proteins is targeted by more than one viral proteins. A snapshot of isolated networks with one (viral) to many (host) interactions are shown in Fig. 3 between viral and host proteins.

Similar researches on SARS-CoV-2 host protein interactions [3]

shows viral protein oriented star-like topology only and unable to report any host protein oriented multiple interactions. We report a list of such highly connected host proteins with the viral proteins (total of 15) in Table 4. Many (viral) to one (host) interactions are also reported (Supplementary-D).

3.4. Distribution of correlation scores

Statistically, it is also important to study the distribution of correlation values (both positive and negative) between pairs of proteins in terms of codon usage patterns. From the distribution plot given in Fig. 4 reveals that the host-viral codon usage pattern (edge correlation) shows non-normal distribution pattern (with $p = 1.13e-42$ for positive correlation, and $p = 7.819e-94$ for negative correlation based on normality test, performed using SciPy.stats.normaltest3) [72,73]. The negative correlation is varied in the range $[-.73, -4.18]$, which covers 6325 (67%) interactions, and a positive correlation is varied in the range $[4.18, 8.44]$, which covers 3087 (33%) interactions. So, positive correlation exhibits a wider range of values than the negative range.

We further look into the correlation value distribution of a viral protein interacting with its target proteins. We report the correlation value range (both positive and negative) for 26 viral proteins in Fig. 4. While fixing τ at high (significance level) value, correlation values also appear to be significant which are ranging between ± 0.05 and above. Except few, most of the viral proteins are participated in the network, both positively and negatively. Viral proteins, Orf10 and Nsp10 are interacted with their targets, negatively. Similarly, viral proteins like N, Nsp1 and Orf7b are interacted, positively.




Fig. 2. Distribution of RSCU scores for 59 codons for all (a) SARS-CoV-2 proteins; (b) Host proteins.

Based on correlation analysis, we may confirm that while a viral protein targets its host, it mimics similar codon usage of its target to uphold the expression of target host protein. Similarly, viral proteins use a set of codons that are rarely used in their targets to down-regulate the expression of its target. We observe in the case of host proteins, involved in signaling pathways, the majority of SARS-CoV-2 proteins aimed to break down the normal pathways by down regulating the key proteins involved in such pathways.

3.5. Degree distribution of host and viral proteins

In any interacting network, the node's degree conveys essential information about the node's influence within the network. In the case of host-viral PPI, a high degree viral protein (highly connected) may be a critical protein that influences the functional activities of a number of host proteins. Pharmacologically, identifying such (hub) proteins may help in designing a small molecule that may bind with it to inhibit its influence during disease pathogenesis. The same may be applicable to host proteins. If host protein have a high degree, it indicates that more viral proteins target the host protein. However, it may require further investigation about its importance in its own network, i.e., host–host protein network. If a host protein is significant concerning its degree, suitable repurposed drug molecules may be identified for the same.

While focusing on highly interacting viral proteins, interestingly, we observe that the maximum number of highly interacting proteins belongs to the non-structural family. In the case of structural proteins, S is a highly interacting (more than 600) protein. Out of accessory proteins, Orf8 shows a maximum interaction count next to protein S.

We report the degree distribution for each of the viral proteins from our network in Fig. 5 (a). From the figure, it can be observed that majority of the viral proteins carrying a high node degree. Out of all the SARS-CoV-2 proteins, Nsp3 shows the maximum degree (≈ 700), which interacts with more than 80% of the candidate host proteins involved in 17 different signaling pathways. Concerning negative edges, Nsp3 is still on top, followed by Nsp16, Nsp13, and few others. While considering positive edges, S, Nsp6, and Orf7a are found to be highly interactive. Few viral proteins like Nsp11, Orf7b, E, Nsp1, Orf10, and Nsp11 are comparatively less interactive.

We show the degree distribution of 859 host proteins in Fig. 5 (b), interacting with 26 viral proteins. From the distribution plot, we can observe that majority (82) of the host proteins are connected with only one viral node. While considering host proteins targeted by multiple viral proteins, we observe less than ten (10) such proteins are highly connected proteins with the degree 21 (maximum within the network). Even though our network is a bipartite graph, we observe that the number of low-degree nodes is high, fav minor in number, which is




Fig. 3. The host-viral interactions network showing host proteins, which are connected to a single viral protein. In the network, the yellow-color represents viral nodes, whereas the blue and green colors represents host nodes, represent positive and negative interactions, respectively. As shown in the figure, 09 viral proteins (Nsp1, Nsp2, Nsp6, Nsp7, Nsp9, M, N, Orf3a, and Orf7a), 08 viral proteins (Nsp3, Nsp5, Nsp10, Nsp11, Nsp12, Nsp16, Orf8, and Orf10), and 03 viral proteins (Nsp13, Nsp14, and Nsp15) interactions with host proteins are positive, negative and both, respectively.

somehow follows the scale-free properties [74] of a complex network. We observe relatively good host nodes possessing a degree within the range of 11 to 18.

3.6. Ranking highly targeted signaling pathways during COVID-19

To study the most affected pathways in our 17 candidate set of pathways, we rank them based on the percentage of host proteins targeted by any SARS-CoV-2 viral protein (out of total proteins involved in those pathways) and report in Fig. 6.

The topmost pathway is the *Mitogen-Activated Protein Kinase (MAPK)* signaling pathway. Different SARS-CoV-2 proteins target more than 50% of proteins from this pathway. This pathway is associated with the COVID-19 immune response [75] and involves in papain-like protease activation of promoter as observed in the SARS coronavirus [76]. MAPK proteins communicate signals from a receptor on the cell's surface to the DNA in the cell's nucleus, essential from a viral infection point of view. Further, MAPK proteins are involved in a series of vital signal transduction pathways that regulate processes such as cell proliferation, cell differentiation, and cell death in humans.

Besides MAPK, other ranked signaling pathways are significantly affected during COVID-19 infection. Under physiological conditions, adipokines act mainly in adipose tissue (paracrine or autocrine) or circulate through the blood to distant target organs, regulating their growth and development, metabolism, and tissue remodeling. However, adipokines' synthesis and secretion are disordered under pathological conditions, leading to obesity, diabetes, heart disease, and other metabolic disorders. Our results show that the *adipocytokine pathway* is affected by COVID-19. It implicates that patients with comorbid conditions like diabetes and heart disease may show the worst disease aggression, which is already observed in various reports. The *mTOR pathway* [12] is a central regulator of mammalian metabolism and physiology, with essential roles in tissues' function, including liver, muscle, white and brown adipose tissue, and the brain. It is dysregulated in human diseases, such as diabetes, obesity, depression, aging-related problems, and certain cancers. Our result corroborates with the same, and it has reported that aged patients are more prone to the infection due to the dysregulation of the mTOR pathway or some other unknown reasons.

It has been observed that some COVID-19 affected deaths are due to

Table 4

The list of top few host proteins targeted by number of SARS-CoV-2 interacting viral proteins. For each host protein (Hp), number of interacting viral proteins (IVP) count and calculated average correlation value (ρ) are shown. There are total of 40 host proteins (20 for positive interactions and 20 for negative interactions).

Sl. No.	Hp	IVP count	Avg. (ρ)	SARS-CoV-2 interacting viral proteins
1	COL4A5	21	0.62	Nsp1, Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
2	STAM2	21	0.63	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf6, Orf7a, Orf8
3	LIFR	21	0.64	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf6, Orf7a, Orf8
4	IFNAR1	20	0.59	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
5	PPM1B	20	0.61	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
6	RPS6KA6	20	0.62	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, N, Orf3a, Orf6, Orf7a, Orf8
7	SOS2	20	0.63	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
8	PKN2	20	0.66	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
9	IRAK4	20	0.69	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
10	IL13RA2	19	0.61	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
11	APAF1	19	0.61	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
12	CUL2	19	0.61	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
13	DNM1L	19	0.63	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
14	MIOS	19	0.64	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
15	BIRC2	19	0.65	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
16	RPS6KA3	19	0.68	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
17	PPP1R3A	19	0.70	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, N, Orf3a, Orf7a, Orf8
18	SGK3	18	0.61	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp8, Nsp9, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
19	PPP3CB	18	0.62	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
20	HIF1A	18	0.62	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp8, Nsp9, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
1	GDF15	19	-0.62	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, Orf3a, Orf6, Orf8
2	FGF4	19	-0.60	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, Orf3a, Orf6, Orf8
3	SHC2	19	-0.58	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, Orf3a, Orf6, Orf8
4	CEBPB	18	-0.59	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
5	IRS2	18	-0.59	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
6	JUN	18	-0.58	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf817
7	EFNA2	18	-0.58	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
8	LPAR5	18	-0.58	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
9	GDF7	18	-0.58	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
10	FZD1	18	-0.58	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf818
11	FZD9	18	-0.57	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
12	PPP2R3B	18	-0.57	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
13	MAPK8IP2	18	-0.57	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
14	DDIT4	18	-0.57	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
15	NOG	18	-0.57	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
16	SMAD6	18	-0.57	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
17	WNT6	18	-0.57	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
18	GREM2	18	-0.57	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
19	BMP7	18	-0.56	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
20	FZD8	18	-0.56	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8

multiple organ failures. *HIF1* [89,90] and *RIG1* [91] like receptor pathways are involved in normal immunoregulation and various organ functioning. Dysregulation may cause immune compromise and multiple organ failure through ischaemic heart disease, acute lung injury, pulmonary hypertension, pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), acute liver failure, liver fibrosis, and acute kidney injury, etc. Our result also supports these findings.

In our ranking, the fourth most affected pathway is the *TGF- β* (*Transforming growth factor-beta*) [92], which is a multi-functional cytokine belonging to the transforming growth factor superfamily that includes three different mammalian isoforms (TGF- β 1 to 3, HGNC symbols TGFB1, TGFB2, TGFB3) and many other signaling proteins. All-white blood cell lineages produce TGF- β proteins. This pathway activates different downstream substrates and regulatory proteins, inducing transcription of various target genes that function in differentiation, chemotaxis, proliferation, and activation of many immune cells.

3.7. Centrality analysis of targeted host proteins and candidate signaling pathways

Studies on human host-viral protein interactions reveal that viruses tend to target- attacks towards host proteins [77,19,78] by interacting with key (central) host proteins. We consider a host protein important if it interacts with many other host proteins in host-host protein network. We use BioGRID [68] to calculate the centrality score of our candidate

host proteins⁵. We report the top 100 central proteins in *Supplementary-A (Table S2)*. We observe that a good number of interacting host proteins in our network are highly central in their own (host) PPI. A common set of viral proteins targets central genes, and such proteins are involved in multiple pathways. For instance, if we consider few top central proteins, MYC (2843), TRIM25 (2656), EGFR (2452), BRCA1 (2236), MDM2 (2219), NTRK1 (2030), KRAS (1944), ELAVL1 (1914) and HSP90AA1 (1734), they are found to be targeted jointly by the viral proteins such Nsp2, Nsp3, Nsp4, Nsp5, Nsp8, Nsp10, Nsp12, Nsp13.

If we consider the most central proteins in our candidate pathways, we observe that the PI3K-Akt signaling pathway (36 target proteins) and MAPK signaling pathway (35 target proteins) contain most of the central proteins targeted by the viral proteins. A pathway may be more crucial from the disease pathogenesis perspective if it contains highly central proteins targeted by viral proteins. Moving one step ahead, we may rank our 17 pathways based on the number of participating central proteins (out of the top 100 centrality list) in the above pathways and shown in *Fig. 7(a)*. More details about the top 100 central host proteins are listed in *Supplementary-A (Table S2)*. Interestingly, in terms of the number of target proteins, which are also central in host-host PPI, the signaling pathway MAPK is one of the worst affected pathways among 17 candidate pathways. In addition to PPI centrality, we study the pathway centrality of the host proteins regarding our 17 signaling pathways.

⁵ <https://thebiogrid.org/>.





Fig. 4. (a) Frequency distribution of positive (right) and negative (left) correlation scores for interacting proteins in terms of RSCU based codon usage similarity. (b) Box plot showing the range of correlation values for each viral protein while associated with its target proteins.

Prior researches also identified an exciting fact that viral proteins target host proteins that are pathway central, i.e., participating in multiple pathways [78]. The degree distribution of host proteins in terms of their density of participation in 17 pathways is reported in Fig. 7(b). We observe a nice power-law [74] like distribution where the majority of proteins are participating in only one pathway, and fewer numbers are having high participation in multiple pathways. We list a few top highly pathway-central proteins and few interesting facts in Table 5. The table shows that the pathway-central proteins are also highly connected in their own PPI and mostly targeted by multiple viral proteins.

3.8. Quantitative association of key pathway proteins and drugs

To investigate further the significance of key proteins in our network, we analyse protein-drug association. We primarily consider approved or under-trial drugs that are in use during COVID-19. We searched online

drug target resource database⁶ to count hits with different key proteins in our network (Supplementary-A, Table S3). We ranked those drugs based on their counts of protein targets in our network (Table 6). A good number of drugs are also observed to be associated with central proteins that are not reported so far used in COVID-19. The list of such drugs is given in Supplementary-A (Table S3). It can be observed from Table 6 that a single drug is having targets in multiple pathways forming a bipartite graph as shown in Fig. 8.

We discuss below the drugs that are associated with COVID-19 and having potential target host proteins involved in our inferred host-viral networks.

Arsenic trioxide is a widely known chemical used for multiple

⁶ <http://www.dgidb.org/>.




Fig. 5. (a) The bar chart represents the host protein count for each viral protein based on correlation analysis (p -value < 0.001). Pc-positive count, Nc-negative count, positive and negative count are based on positive and negative correlations. (b) Degree distribution of 859 host proteins in terms of number of associated viral proteins (degree) count (x-axis) with host protein frequency (y-axis).




Fig. 6. Ranking of 17 candidate signaling pathways. The pathway ranking is done by observing the host protein percentage from pathways that interact with any of the SARS-CoV-2 (26) proteins.

disease conditions. The Ministry of Ayush⁷, Govt. Of India, advised for *Arsenicum album 30* as a potential homeopath drug for COVID-19. Arsenic trioxide is a mother tincture of *Arsenicum album 30*, used as a homeopath medicine. Symptoms like severe respiratory adverse effects frequently occur in patients with promyelocytic leukemia. Arsenic trioxide could be used in consolidation therapy [79,80]. If we consider central genes (present in the top 100 list) involved in MAPK pathways, we observe that six target proteins (RARA, FGFR1, IKKBK, CCND1, CDKN1A, JUN, MAPK3, AKT1) are the excellent target of this chemical. Interestingly, all such proteins are targeted negatively by viral proteins. In a comorbid situation where these signaling pathway genes are already perturbed, arsenic trioxide may play a protective role in boosting up the immunity and other unknown vital regulators that are yet to discover. In addition to MAPK, several targets are present in PI3K-Akt, TNF, and Apoptosis signaling pathways.

Dexamethasone is another most widely used COVID-19 drug with

64 target genes⁸. This is the first drug to show life-saving efficacy in patients infected with COVID-19 [81] and widely utilized in a large trial in the UK [82]. Our result shows that NTRK1, HSPA8, SMAD3, VCAM1, and RARA are the targets (central) for the drug involved in MAPK, PI3K-Akt, Th17 cell differentiation, TGF- β , and NF- κ B. In addition to that, Dexamethasone also targets a few other interacting host proteins (low centrality), JUNB, LIF, CD86, SLC2A4, and IRS2. Dexamethasone is predicted to maintain these signaling pathways' normal functioning and shows protection against COVID-19 symptoms, as we assume from our results.

Hydroxychloroquine is another important drug, has been widely utilized for COVID-19 treatment [83,84]. The only central target is TNF, which is present in several signaling pathways. It can rapidly be transcribed in various cell types following exposure to a broad range of pathogens and signals of inflammation and stress [85]. Other low centrality targets are TLR3, TLR7, PTGS2, and TLR9.

⁷ www.ayush.gov.in.

⁸ <http://www.dgidb.org/>.




Fig. 7. (a) Participation host protein count of central proteins in candidate pathways; (b) Degree distribution of 859 interacting host proteins in terms of number of associated signaling pathways (candidate).

Table 5

Few top pathway central proteins with the number of pathways they are participating (out of 17 pathways), PPI centrality score and number of viral proteins (Vp) targeting the proteins.

Host protein	#Pathway centrality	PPI centrality	Interacting Vp count
IKBKB	13	552	2
CHUK	12	462	11
MAPK3	12	337	16
RELA	12	859	10
AKT1	11	886	11
AKT2	11	113	12
AKT3	11	61	15
IKBKG	11	959	9
TNF	11	497	11
MAPK8	9	444	12
MAPK9	9	260	15
NFKBIA	9	501	8
PIK3CA	9	190	19
PIK3CB	9	82	17
PIK3CD	9	28	17
PIK3R1	9	684	5
PIK3R2	9	190	16

The other two important drugs recommended by WHO⁹ are **Ritonavir**, and **Interferon Alfa B** observed in our list used for the COVID-19 clinical trial [86–88]. Interestingly, we found that ritonavir shows three target central genes (CXCL10, TLR4, IFNL3) in our study. These genes share NF κ B, HIF1, toll-like receptor, PI3K-AKT, JAK-STAT, cytokine-cytokine receptor, TNF, IL7, RIG1 receptor, chemokine signaling pathways. **Interferon Alfa 1B** is another option for solidarity trials with targets like IFNAR1, IFNAR2, and IL13 genes. These genes participate in PI3K-AKT, toll-like receptor, cytokine-cytokine receptor, JAK-STAT, IL17 pathways. These pathways are essential for maintaining normal immunological functioning, which is thought to dysregulate in COVID-19.

We believe that a pathway targeted by different SARS-CoV-2 proteins and involvement of highly central proteins in its own PPI is the most crucial (affected) pathway. It is worth mentioning that the above-highlighted drug molecules are based on quantitative analysis of host proteins from our inferred host-viral network and their hits with the existing drug target database. Hence, our proposed scheme is not a new drug repurposing methodology and needs due attention while designing

Table 6

Few COVID-19 drugs with their actual number of target host proteins from our inferred network, number of targets that are highly central and number of targets involved in candidate pathways.

Drug Name	#Actual targets	#Targets in inferred networks	#Targets (central) in top-100 host PPI	#Involved pathway
Arsenic trioxide	25	11	8	16
Dexamethasone	64	10	5	12
Hydroxychloroquine	9	5	1	11
Interferon beta	5	4	0	9
Ritonavir	15	3	0	10

therapeutic solutions pharmacologically.

4. Conclusion

This work introduced a novel effort into recreating host-viral PPI. Proposed work explored the codon usage pattern similarity between host proteins that are participating in a few major signaling pathways and SARS-CoV-2 viral proteins. Both positive and negative edges between interacting proteins were inferred, which depict an essential association between viral and host proteins. The inferred network was analyzed topologically, considering nodes' degree distribution and node centrality. An interesting fact has been observed on how viral proteins are targeting their host proteins. Our analysis highlighted a few drugs already in use for COVID-19, having potential targets in some of the essential host proteins involved in important candidate signaling pathways such as MAPK and PI3K-Akt. Several central proteins were identified (AKT1, CCND1, CDKN1A, FGFR1, HSPA8, IKBKB, JUN, MAPK3, NTRK1, RARA, SMAD3, TNF, and VCAM1), which are involved in critical signaling pathways and targeted by few drug molecules. The topmost few drug molecules highlighted by this study are *Arsenic trioxide*, *Dexamethasone*, and *Hydroxychloroquine*, which might play an influential role in preventing COVID-19 mortality.

Our method is generic and useful to draw a more extensive network, covering genes from all critical pathways. Even the method can be applied to any set of host-viral proteins (other than SARS-CoV-2 or Human). Currently, we used a correlation score to measure the similarity between two RSCU vectors. However, other measures such as cosine similarity, mutual information, and ensemble approach might improve the result. One may consider a multi-layer network approach considering viral-viral and host-host networks that may shed better

⁹ www.who.int.




Fig. 8. Bipartite graph showing 19 drugs linked with 17 signaling pathways. Left and right panel are showing drug name and middle panel is showing signaling pathway name.

light on the possible viral-host interaction patterns.

Acknowledgement

This research is partly supported by the Department of Science & Technology (DST), Govt. of India under DST-ICPS Data Science program [DST/ICPS/Cluster/Data Science/General]. Thanks to Ms Arpita Roy, for reviewing and correcting the final draft of the manuscript.

CRedit authorship contribution statement

Jayanta Kumar Das: Conceptualization, Data curation, Methodology, Software, Formal analysis, Visualization, Writing - original draft, Writing - review & editing. **Subhadip Chakraborty:** Software, Validation, Visualization, Writing - original draft, Writing - review & editing. **Swarup Roy:** Conceptualization, Supervision, Visualization, Writing - original draft, Writing - review & editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary material

Supplementary data associated with this article can be found, in the online version, at <https://doi.org/10.1016/j.jbi.2021.103801>.

References

[1] D. Wrapp, N. Wang, K.S. Corbett, J.A. Goldsmith, C.-L. Hsieh, O. Abiona, B. S. Graham, J.S. McLellan, Cryo-em structure of the 2019-ncov spike in the prefusion conformation, *Science* 367 (2020) 1260–1263.
 [2] U. Jain, Effect of covid-19 on the organs, *Cureus* 12 (2020).
 [3] D.E. Gordon, G.M. Jang, M. Bouhaddou, J. Xu, K. Obernier, K.M. White, M. J. O’Meara, V.V. Rezelj, J.Z. Guo, D.L. Swaney, et al., A sars-cov-2 protein interaction map reveals targets for drug repurposing, *Nature* (2020) 1–13.

[4] Y. Zhou, Y. Hou, J. Shen, Y. Huang, W. Martin, F. Cheng, Network-based drug repurposing for novel coronavirus 2019-ncov/sars-cov-2, *Cell Discovery* 6 (2020) 1–18.
 [5] B.R. Beck, B. Shin, Y. Choi, S. Park, K. Kang, Predicting commercially available antiviral drugs that may act on the novel coronavirus (sars-cov-2) through a drug-target interaction deep learning model, *Comput. Struct. Biotechnol. J.* (2020).
 [6] V. Memišević, N. Zavaljevski, S.V. Rajagopala, K. Kwon, R. Pieper, D. DeShazer, J. Reifman, A. Wallqvist, Mining host-pathogen protein interactions to characterize burkholderia mallei infectivity mechanisms, *PLoS Comput. Biol.* 11 (2015) e1004088.
 [7] A. Pichlmair, K. Kandasamy, G. Alvisi, O. Mulhern, R. Sacco, M. Habjan, M. Binder, A. Stefanovic, C.-A. Eberle, A. Goncalves, et al., Viral immune modulators perturb the human molecular network by common and unique strategies, *Nature* 487 (2012) 486–490.
 [8] R. Draenert, J. Frater, J.G. Prado, Virus immune evasion: new mechanism and implications in disease outcome, 2012.
 [9] A. Kieser, Signal transduction by viral factors: critical interface between the virus and its host cell with implications for the viral life cycle and disease development, *Signal Transduction* 7 (2007) 3–4.
 [10] F. Seif, H. Aazami, M. Khoshmirsafa, M. Kamali, M. Mohsenzadegan, M. Pornour, D. Mansouri, Jak inhibition as a new treatment strategy for patients with covid-19, *Int. Arch. Allergy Immunol.* 181 (2020) 467–475.
 [11] D. Wu, X.O. Yang, Th17 responses in cytokine storm of covid-19: An emerging target of jak2 inhibitor fedratinib, *J. Microbiol., Immunol. Infect.* 53 (2020) 368–370.
 [12] H. Ganesan, V. Balasubramanian, M. Iyer, A. Venugopal, M.D. Subramaniam, S.-G. Cho, B. Vellingiri, mTOR signalling pathway-a root cause for idiopathic autism? *BMB Reports* 52 (2019) 424.
 [13] W. Luo, Y.-X. Li, L.-J. Jiang, Q. Chen, T. Wang, D.-W. Ye, Targeting jak-stat signaling to control cytokine release syndrome in covid-19, *Trends Pharmacol. Sci.* (2020).
 [14] T. Shibabaw, Inflammatory cytokine: Il-17a signaling pathway in patients present with covid-19 and current treatment strategy, *J. Inflammat. Res.* 13 (2020) 673.
 [15] J.M. Grimes, K.V. Grimes, p38 mapk inhibition: A promising therapeutic approach for covid-19, *J. Mol. Cell. Cardiol.* (2020).
 [16] J. Li, M. Guo, X. Tian, X. Wang, X. Yang, P. Wu, C. Liu, Z. Xiao, Y. Qu, Y. Yin, et al., Virus-host interactome and proteomic survey of pbmcs from covid-19 patients reveal potential virulence factors influencing sars-cov-2 pathogenesis, *Med* (2020), <https://doi.org/10.1016/j.medj.2020.07.002>.
 [17] F. Messina, E. Giombini, C. Agrati, F. Vairo, T.A. Bartoli, S. Al Moghazi, M. Piacentini, F. Locatelli, G. Kobinger, M. Maeurer, et al., Covid-19: viral-host interactome analyzed by network based-approach model to study pathogenesis of sars-cov-2 infection, *J. Translat. Med.* 18 (2020) 1–10.
 [18] J. Kumar Das, G. Tradigo, P. Veltri, P.H. Guzzi, S. Roy, Data science in unveiling covid-19 pathogenesis and diagnosis: evolutionary origin to drug repurposing, *Briefings Bioinformat.* 22 (2021) 855–872.

- [19] V. Navratil, B. de Chasse, C.R. Combe, V. Lotteau, When the human viral infectome and disease networks collide: towards a systems biology platform for the aetiology of human diseases, *BMC Syst. Biol.* 5 (2011) 13.
- [20] M.D. Dyer, T. Murali, B.W. Sobral, The landscape of human proteins interacting with viruses and other pathogens, *PLoS Pathog* 4 (2008) e32.
- [21] O. Kuchaiev, M. Rašajski, D.J. Higham, N. Pržulj, Geometric de-noising of protein-protein interaction networks, *PLoS Comput. Biol.* 5 (2009) e1000454.
- [22] Y. Murakami, K. Mizuguchi, Homology-based prediction of interactions between proteins using averaged one-dependence estimators, *BMC Bioinform.* 15 (2014) 213.
- [23] L. Salwinski, D. Eisenberg, Computational methods of analysis of protein-protein interactions, *Current Opin. Struct. Biol.* 13 (2003) 377–382.
- [24] Q.C. Zhang, D. Petrey, L. Deng, L. Qiang, Y. Shi, C.A. Thu, B. Bisikirska, C. Lefebvre, D. Accili, T. Hunter, et al., Structure-based prediction of protein-protein interactions on a genome-wide scale, *Nature* 490 (2012) 556–560.
- [25] R. Singh, D. Park, J. Xu, R. Hosur, B. Berger, Struct2net: a web service to predict protein-protein interactions using a structure-based approach, *Nucleic Acids Res.* 38 (2010) W508–W515.
- [26] S. Jain, G.D. Bader, An improved method for scoring protein-protein interactions using semantic similarity within the gene ontology, *BMC Bioinform.* 11 (2010) 1–14.
- [27] X. Yang, S. Yang, Q. Li, S. Wuchty, Z. Zhang, Prediction of human-virus protein-protein interactions through a sequence embedding-based machine learning method, *Comput. Struct. Biotechnol. J.* 18 (2020) 153–161.
- [28] S. Alguwaizani, B. Park, X. Zhou, D.-S. Huang, K. Han, Predicting interactions between virus and host proteins using repeat patterns and composition of amino acids, *J. Healthcare Eng.* 2018 (2018).
- [29] M. Dilucca, S. Forcelloni, A.G. Georgakilas, A. Giansanti, A. Pavlopoulou, Codon usage and phenotypic divergences of sars-cov-2 genes, *Viruses* 12 (2020) 498.
- [30] P.M. Sharp, L.R. Emery, K. Zeng, Forces that influence the evolution of codon bias, *Philosoph. Trans. Roy. Soc. B: Biol. Sci.* 365 (2010) 1203–1212.
- [31] G.M. Jenkins, E.C. Holmes, The extent of codon usage bias in human RNA viruses and its evolutionary origin, *Virus Res.* 92 (2003) 1–7.
- [32] M. Gale, S.-L. Tan, M.G. Katze, Translational control of viral gene expression in eukaryotes, *Microbiol. Molecular Biol. Rev.* 64 (2000) 239–280.
- [33] G. Lithwick, H. Margalit, Relative predicted protein levels of functionally associated proteins are conserved across organisms, *Nucleic Acids Res.* 33 (2005) 1051–1057.
- [34] H.B. Fraser, A.E. Hirsh, D.P. Wall, M.B. Eisen, Coevolution of gene expression among interacting proteins, *Proc. Nat. Acad. Sci.* 101 (2004) 9033–9038.
- [35] I. Bahir, M. Fromer, Y. Prat, M. Linial, Viral adaptation to host: a proteome-based analysis of codon usage and amino acid preferences, *Molecular Syst. Biol.* 5 (2009) 311.
- [36] Z. Zhou, Y. Dang, M. Zhou, L. Li, C.-H. Yu, J. Fu, S. Chen, Y. Liu, Codon usage is an important determinant of gene expression levels largely through its effects on transcription, *Proc. Nat. Acad. Sci.* 113 (2016) E6117–E6125.
- [37] K. Jitobaom, S. Phakaratsakul, T. Sirihongthong, S. Chotewutmontri, P. Suriyaphol, O. Suptawitaw, P. Auewarakul, Codon usage similarity between viral and some host genes suggests a codon-specific translational regulation, *Heliyon* 6 (2020) e03915.
- [38] H. Song, H. Gao, J. Liu, P. Tian, Z. Nan, Comprehensive analysis of correlations among codon usage bias, gene expression, and substitution rate in arachis duranensis and arachis ipaensis orthologs, *Sci. Rep.* 7 (2017) 1–12.
- [39] M. Dos Reis, L. Wernisch, R. Savva, Unexpected correlations between gene expression and codon usage bias from microarray data for the whole *Escherichia coli* K-12 genome, *Nucleic Acids Res.* 31 (2003) 6976–6985.
- [40] J.L. Chaney, P.L. Clark, Roles for synonymous codon usage in protein biogenesis, *Annual Rev. Biophys.* 44 (2015) 143–166.
- [41] Y. Zhou, Y.-S. Zhou, F. He, J. Song, Z. Zhang, Can simple codon pair usage predict protein-protein interaction? *Mol. Biosyst.* 8 (2012) 1396–1404.
- [42] X. Peng, J. Wang, W. Peng, F.-X. Wu, Y. Pan, Protein-protein interactions: detection, reliability assessment and applications, *Briefings Bioinform.* 18 (2016) 798–819.
- [43] V.S. Rao, K. Srinivas, G. Sujini, G. Kumar, Protein-protein interaction detection: methods and analysis, *Int. J. Proteom.* 2014 (2014).
- [44] R. Grantham, C. Gautier, M. Gouy, R. Mercier, A. Pave, Codon catalog usage and the genome hypothesis, *Nucleic Acids Res.* 8 (1980) 197.
- [45] Y.-S. Liu, J.-H. Zhou, H.-T. Chen, L.-N. Ma, Z. Pejsak, Y.-Z. Ding, J. Zhang, The characteristics of the synonymous codon usage in enterovirus 71 virus and the effects of host on the virus in codon usage pattern, *Infection, Genetics Evol.* 11 (2011) 1168–1173.
- [46] J.B. Plotkin, H. Robins, A.J. Levine, Tissue-specific codon usage and the expression of human genes, *Proc. Nat. Acad. Sci.* 101 (2004) 12588–12591.
- [47] S. Mueller, D. Papamichail, J.R. Coleman, S. Skiena, E. Wimmer, Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity, *J. Virol.* 80 (2006) 9687–9696.
- [48] R.W. Tindle, Immune evasion in human papillomavirus-associated cervical cancer, *Nat. Rev. Cancer* 2 (2002) 59–64.
- [49] F. Wu, S. Zhao, B. Yu, Y.-M. Chen, W. Wang, Z.-G. Song, Y. Hu, Z.-W. Tao, J.-H. Tian, Y.-Y. Pei, et al., A new coronavirus associated with human respiratory disease in China, *Nature* 579 (2020) 265–269.
- [50] J.K. Das, S. Roy, A study on non-synonymous mutational patterns in structural proteins of sars-cov-2, *Genome* (2021), <https://doi.org/10.1139/gen-2020-0157>.
- [51] M.A.-A.-K. Khan, A.B.M.M.K. Islam, Sars-cov-2 proteins exploit host's genetic and epigenetic mediators for the annexation of key host signaling pathways, *Front. Mol. Biosci.* 7 (2020).
- [52] L. Chen, H. Deng, H. Cui, J. Fang, Z. Zuo, J. Deng, Y. Li, X. Wang, L. Zhao, Inflammatory responses and inflammation-associated diseases in organs, *Oncotarget* 9 (2018) 7204.
- [53] Z. Zhao, J. Xia, O. Tastan, I. Singh, M. Kshirsagar, J. Carbonell, J. Klein-Seetharaman, Virus interactions with human signal transduction pathways, *Int. J. Comput. Biol. Drug Des.* 4 (2011) 83–105.
- [54] R. Khandia, S. Singhal, U. Kumar, A. Ansari, R. Tiwari, K. Dhama, J. Das, A. Munjal, R.K. Singh, Analysis of nipah virus codon usage and adaptation to hosts, *Front. Microbiol.* 10 (2019) 886.
- [55] P.M. Sharp, T.M. Tuohy, K.R. Musurski, Codon usage in yeast: cluster analysis clearly differentiates highly and lowly expressed genes, *Nucleic Acids Res.* 14 (1986) 5125–5143.
- [56] P.M. Sharp, W.-H. Li, An evolutionary perspective on synonymous codon usage in unicellular organisms, *J. Molecul. Evol.* 24 (1986) 28–38.
- [57] M. Dilucca, S. Forcelloni, G. Cimini, A. Giansanti, Co-evolution between codon usage and protein-protein interaction networks in bacterial genomes, *bioRxiv* (2020).
- [58] H.S. Najafabadi, R. Salavati, Sequence-based prediction of protein-protein interactions by means of codon usage, *Genome Biol.* 9 (2008) 1–9.
- [59] J. Das, S. Roy, Comparative analysis of human coronaviruses focusing on nucleotide variability and synonymous codon usage pattern, *BioRxiv* (2020).
- [60] P.L. Meintjes, A.G. Rodrigo, Evolution of relative synonymous codon usage in human immunodeficiency virus type-1, *J. Bioinformatics Comput. Biol.* 3 (2005) 157–168.
- [61] Y. Chen, Q. Xu, X. Yuan, X. Li, T. Zhu, Y. Ma, J.-L. Chen, Analysis of the codon usage pattern in middle east respiratory syndrome coronavirus, *Oncotarget* 8 (2017) 110337.
- [62] B.D. Lee, Python implementation of codon adaptation index, *J. Open Source Softw.* 3 (2018) 903, <https://doi.org/10.21105/joss.00905>.
- [63] P.H. Guzzi, S. Roy, *Biological Network Analysis: Trends, Approaches, Graph Theory, and Algorithms*, Academic Press, 2020.
- [64] B.G. Häne, K. Jäger, H.G. Drexler, The Pearson product-moment correlation coefficient is better suited for identification of DNA fingerprint profiles than band matching algorithms, *Electrophoresis* 14 (1993) 967–972.
- [65] J. Benesty, J. Chen, Y. Huang, I. Cohen, Pearson correlation coefficient, in: *Noise Reduction in Speech Processing*, Springer, 2009, pp. 1–4.
- [66] P. Sedgwick, Pearson's correlation coefficient, *Bmj* 345 (2012) e4483.
- [67] A. Stukalov, V. Girault, V. Grass, V. Bergant, O. Karayel, C. Urban, D.A. Haas, Y. Huang, L. Oubraham, A. Wang, et al., Multi-level proteomics reveals host-perturbation strategies of sars-cov-2 and sars-cov, *Biorxiv* (2020).
- [68] C. Stark, B.-J. Breitkreutz, T. Reguly, L. Boucher, A. Breitkreutz, M. Tyers, Biogrid: a general repository for interaction datasets, *Nucleic Acids Res.* 34 (2006) D535–D539.
- [69] A. Chatr-Aryamontri, A. Ceol, D. Peluso, A. Nardozza, S. Panni, F. Sacco, M. Tinti, A. Smolyar, L. Castagnoli, M. Vidal, et al., Virusmint: a viral protein interaction database, *Nucleic Acids Res.* 37 (2009) D669–D673.
- [70] W. Gu, T. Zhou, J. Ma, X. Sun, Z. Lu, Analysis of synonymous codon usage in sars coronavirus and other viruses in the nidovirales, *Virus Res.* 101 (2004) 155–161.
- [71] A. Sheikh, A. Al-Taher, M. Al-Nazawi, A.I. Al-Mubarak, M. Kandeel, Analysis of preferred codon usage in the coronavirus n genes and their implications for genome evolution and vaccine design, *J. Virol. Methods* 277 (2020) 113806.
- [72] R.B. d'Agostino, An omnibus test of normality for moderate and large size samples, *Biometrika* 58 (1971) 341–348.
- [73] R. D'Agostino, E.S. Pearson, Tests for departure from normality. empirical results for the distributions of b_2 and b , *Biometrika* 60 (1973) 613–622.
- [74] R. Albert, A.-L. Barabási, Statistical mechanics of complex networks, *Reviews Modern Phys.* 74 (2002) 47.
- [75] L. Huang, Y. Shi, B. Gong, L. Jiang, X. Liu, J. Yang, J. Tang, C. You, Q. Jiang, B. Long, et al., Blood single cell immune profiling reveals the interferon-mapk pathway mediated adaptive immune response for covid-19, *MedRxiv* (2020).
- [76] S.-W. Li, C.-Y. Wang, Y.-J. Jou, T.-C. Yang, S.-H. Huang, L. Wan, Y.-J. Lin, C.-W. Lin, Sars coronavirus papain-like protease induces egr-1-dependent up-regulation of tgf- β 1 via ros/p38 mapk/stat3 pathway, *Sci. Reports* 6 (2016) 1–13.
- [77] R. Albert, H. Jeong, A.-L. Barabási, Error and attack tolerance of complex networks, *Nature* 406 (2000) 378–382.
- [78] R.R. Halehalli, H.A. Nagarajaram, Molecular principles of human virus protein-protein interactions, *Bioinformatics* 31 (2015) 1025–1033.
- [79] M. Gavillet, J.C. Klappert, O. Spertini, S. Blum, Acute leukemia in the time of covid-19, *Leukemia Res.* 92 (2020) 106353.
- [80] F. Ferrara, P. Zappasodi, E. Roncoroni, E. Borlenghi, G. Rossi, Impact of covid-19 on the treatment of acute myeloid leukemia, *Leukemia* 34 (2020) 2254–2256.
- [81] T. Lammers, A.M. Sofias, R. van der Meel, R. Schifflers, G. Storm, F. Tacke, S. Koschmieder, T.H. Brümmerdorf, F. Kiessling, J.M. Metselaar, Dexamethasone nanomedicines for covid-19, *Nature Nanotechnol.* 15 (2020) 622–624.
- [82] T. Theoharides, P. Conti, Dexamethasone for covid-19? not so fast, *J. Biol. Regul. Homeost. Agents* 34 (2020) 10–23812.
- [83] Z. Chen, J. Hu, Z. Zhang, S. Jiang, S. Han, D. Yan, R. Zhuang, B. Hu, Z. Zhang, Efficacy of hydroxychloroquine in patients with covid-19: results of a randomized clinical trial, *medrxiv* (2020).
- [84] C.P. Skipper, K.A. Pastick, N.W. Engen, A.S. Bangdiwala, M. Abassi, S.M. Lofgren, D.A. Williams, E.C. Okafor, M.F. Pullen, M.R. Nicol, et al., Hydroxychloroquine in nonhospitalized adults with early covid-19: a randomized trial, *Annals Internal Med.* 173 (2020) 623–631.

- [85] J.V. Falvo, A.V. Tsytyskova, A.E. Goldfeld, Transcriptional control of the *tnf* gene, *TNF Pathophysiol.* 11 (2010) 27–60.
- [86] P. Dalerba, B. Levin, J.L. Thompson, A trial of lopinavir-ritonavir in covid-19, *New Engl. J. Med.* 382 (2020).
- [87] X. Ye, Y. Luo, S. Xia, Q. Sun, J. Ding, Y. Zhou, W. Chen, X. Wang, W. Zhang, W. Du, et al., Clinical efficacy of lopinavir/ritonavir in the treatment of coronavirus disease 2019, *Eur. Rev. Med. Pharmacol. Sci.* 24 (2020) 3390–3396.
- [88] L. Zha, S. Li, L. Pan, B. Tefsen, Y. Li, N. French, L. Chen, G. Yang, E.V. Villanueva, Corticosteroid treatment of patients with coronavirus disease 2019 (covid-19), *Med. J. Aust.* 212 (2020) (2019) 416–420.
- [89] P. Maxwell, HIF-1: an oxygen response system with special relevance to the kidney, *J. Am. Soc. Nephrol.* 14 (11) (2003) 2712–2722.
- [90] M. Jahani, D. Sadat, M. Kamran, Hypoxia: A key feature of COVID-19 launching activation of HIF-1 and cytokine storm, *J. Inflamm.* 17 (1) (2020) 1–10.
- [91] T. Kawai, A. Shizuo, Toll-like receptor and RIG-1-like receptor signaling, *Ann. NY. Acad. Sci.* 1143 (1) (2008) 1–20.
- [92] C. Larson, et al., TGF-beta: a master immune regulator, *Expert Opin. Ther. Targets* 24 (5) (2020) 427–438.